United States Allergic Rhino-Conjunctivitis Market 2025 | Growth Drivers, Key Players & Investment Opportunities

Market Size and Growth

Allergic Rhino-Conjunctivitis Market is expected to grow With a High CAGR during the forecast period (2024-2031).

Key Development:

United States: Recent Industry Developments

✅ In September 2025, Regeneron Pharmaceuticals announced positive Phase 3 trial results of its novel allergen-blocking antibodies for cat and birch allergies, showing significant reductions in ocular itch and conjunctival redness in adults. This development paves the way for future treatments of allergic rhino-conjunctivitis.

✅ In August 2025, the FDA approved RAGWITEK® (short ragweed pollen allergen tablet) for children and adolescents aged 5-17 years with ragweed-pollen-induced allergic rhinitis with or without conjunctivitis. The approval marks a milestone in sublingual immunotherapy for seasonal rhino-conjunctival allergies.

✅ In March 2025, Olopatadine Hydrochloride Ophthalmic Solution 0.2% obtained FDA final approval for over-the-counter use in the U.S. for allergic conjunctivitis, providing a new accessible therapy for eye symptoms associated with allergic rhino-conjunctivitis.

✅ In February 2025, the FDA approved ODACTRA® (house dust mite allergen extract tablet) for children aged 5-11 years with house dust-mite-induced allergic rhinitis with or without conjunctivitis. The approval expands the pediatric population eligible for sublingual immunotherapy.

Japan: Recent Industry Developments

✅ In September 2025, neffy® (epinephrine nasal spray) was approved in Japan as the first needle-free emergency treatment of severe allergic reactions (anaphylaxis), broadening the allergy ecosystem and supporting rapid intervention for allergic conditions.

✅ In April 2025, Torii Pharmaceutical Co., Ltd. registered a Phase III clinical trial in Japan for grass-pollen-induced rhinoconjunctivitis, with endpoints including rhinitis and conjunctivitis symptom scores, reflecting ongoing development in rhino-ocular allergy therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/allergic-rhino-conjunctivitis-market?sb

Recent Mergers and acquisitions:

United States: Recent Industry M&A / Business Deals

✅ In May 2025, ARS Pharmaceuticals, Inc. entered into a four-year co-promotion agreement with ALK-Abelló A/S to jointly commercialize the intranasal epinephrine product "neffy®" in the U.S., expanding access in the allergy emergency-treatment segment and strengthening pediatric outreach.

✅ In November 2024, ARS Pharmaceuticals signed a licensing deal with ALK-Abelló granting exclusive rights outside the U.S. for neffy®, receiving a significant upfront payment with potential milestone-based earn-outs, enhancing its global allergy-treatment footprint.

(Note: These deals are strategic licensing/co-promotion agreements reflecting business consolidation and expansion in the allergy-therapeutics space in the U.S.)

Japan: Recent Industry M&A / Business Deals

✅ In May 2025, Shionogi & Co., Ltd. executed an agreement to acquire the pharmaceutical business of Japan Tobacco Inc. through a company split, expanding its portfolio in Japan's allergy and therapeutic areas and strengthening domestic market position.

✅ In February 2025, U.S. private-equity firm Bain Capital agreed to acquire Mitsubishi Tanabe Pharma Corporation (Japan) for approximately US $3.3 billion, reflecting growing overseas investment and consolidation in the Japanese pharmaceutical and allergy-treatment sector.

Key Players:

=> Sun Pharmaceutical Industries, Merck & Co., Inc, Novartis AG, Haleon Group, Lofarma S.p.A, ALK-Abello A/S, Stallergenes Greer, HAL Allergy B.V., Hikma Pharmaceuticals PLC, Bausch & Lomb and among others.

Growth Forecast Projected:

The Global Allergic Rhino-Conjunctivitis Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Allergic Rhino-Conjunctivitis Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=allergic-rhino-conjunctivitis-market

Key Segments:

➥ By Drug Type: Corticosteroids (Nasal and Topical), Decongestants, Antihistamines, Mast Cell Stabilizers, Others
➥ By Route of Administration: Oral, Nasal, Topical, Others
➥ By Age Group: Pediatric, Adult
➥ By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Regional Analysis for Allergic Rhino-Conjunctivitis Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Allergic Rhino-Conjunctivitis producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Allergic Rhino-Conjunctivitis revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/allergic-rhino-conjunctivitis-market?sb

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.